MedTrace Logo

Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients

NCT05915676 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-06-23

No results posted yet for this study

Summary

1. To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.
2. To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.

Conditions

Interventions

DIAGNOSTIC_TEST

Leukocyte Immunoglobulin-like receptors A3

Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Zahraa Abou eleyoun, PHD · Assiut University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-06-01
Completion
2024-07-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05915676 on ClinicalTrials.gov